Robert Walmsley


Research scientist currently completing a PhD at the University of Leeds working on cell death mechanisms in endogenous cardiac progenitor cells from receptor tyrosine kinase inhibitors.

Completed BSc in applied biomedical science with a clinical placement and became a HCPC registered biomedical scientist in 2014 at Aston University, Birmingham. Carried out MSc in stem cells and regenerative medicine at Aston University, Birmingham. The masters involved a project on the Integration of precursor derived glial cells into anatomically intact brain tissue.

Research interests

Mechanism of cell death in human cardiac progenitor cells after anti-cancer treatment.

My particular focus at present is understanding how receptor tyrosine kinase inhibitors (RTKIs) are causing cell death within human cardiac progenitor cells (hCPCs). My primary focus is determining the cell death pathways involved in hCPCs after RTKI treatment by looking at specific signalling pathways; apoptosis, necroptosis, necrosis and autophagy. I also intend to determine whether the RTKI toxicity is linked to changes in calcium dynamics and reactive oxygen species signalling. The overall aim of this research is to find a targeted pathway which can be exploited to overcome the cell death within the hCPCs without interfering with the RTKIs action as a cancer therapy. 


Burke et. al. Toxicology in Vitro (2019). "Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro". 



  • PhD candidate (present), LARS scholarship, University of Leeds
  • MSc 2015 in Stem Cells and Regenerative Medicine
  • BSc in Applied Biomedical Science 2014 with clinical placement

Research groups and institutes

  • Cardiovascular